A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss
Researchers must understand that this compound is investigational and not FDA approved for any medical indication
Selective NNMT inhibition as a strategy for metabolic disease
Long R3 IGF-1, Long Arginine 3-IGF-1, LR3-IGF-1 20-30 hours (vs 12-15 minutes for native IGF-1) IGF-1 LR3 (Long R3 IGF-1) is a modified insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension
BPC-157 may be less appropriate for those with a history of cancer or active malignancy, individuals uncomfortable with the investigational nature of peptide therapy, people unable to commit to consistent daily administration for 4-8 weeks, those seeking instant results rather than gradual healing, and anyone who cannot source pharmaceutical-grade products from reputable suppliers
Elevated NAD+ enhances mitochondrial function, promotes increased ATP production, and stimulates fat oxidation